Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery

Journal of Extra-Corporeal Technology

Volumn 40, Issue 4, 2008, Pages 241-248

  Niles, Scott D ^a,b   Burkhart, Harold M ^a   Duffey, David A ^a   Buhrman, Keri ^a   Burzynski, Jeffrey ^a   Holt, David W ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary bypass; NovoSeven; Pediatric; Recombinant factor viia; RFVIIa

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; BLOOD COMPONENT THERAPY; BODY WEIGHT; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; EVALUATION; HEALTH CARE UTILIZATION; HEART SURGERY; HOSPITAL ADMISSION; HUMAN; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; OFF LABEL DRUG USE; PARTIAL THROMBOPLASTIN TIME; PEDIATRIC SURGERY; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN TIME; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; BLOOD CLOTTING; BLOOD TRANSFUSION; FEMALE; MALE; METHODOLOGY; POSTPARTUM HEMORRHAGE; THORAX SURGERY;

BLOOD COAGULATION; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; FACTOR VIIA; FEMALE; HUMANS; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; MALE; PARTIAL THROMBOPLASTIN TIME; POSTPARTUM HEMORRHAGE; PROTHROMBIN TIME; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THORACIC SURGERY;

EID: 61449215130     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Arnold P, Jackson S, Wallis J, Smith J, Bolton D, Haynes S. Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med. 2001;27:1395-400.
2. Dominguez T, Mitchell M, Friess SH, et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2005;6:348-51.
3. Egan JR, Lammi A, Schell DN, Gillis J, Nunn GR. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med. 2004;30:682-5.
4. MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: Clinical experiences and associated outcomes. Transfusion. 2005;45:1434-42.
5. Pychynska-Pokorsda M. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med. 2004;5:246-50.
6. Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth. 2005;15:235-40.
7. Tobias JD, Groeper K, Berkenbosch JW. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J. 2003;96:12-6.
8. Tobias JD, Simsic JM, Weinstein S, Schechter W, Kartha V, Michler R. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med. 2004;19:270-3.
9. Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med. 2005;6:473-6.
10. Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs. 1999;23:979-83.
11. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005;80:66-71.
12. Bui J, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002;124:852-4.
13. De Gasperi A. Intraoperative use of recombinant activated factor VII (rFVIIa). Minerva Anestesiol. 2006;72:489-94.
14. DiDomenico RJ, Massad MG, Kpodonu J, Navarro RA, Geha AS. Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest. 2005;127:1828-35.
15. von Heymann C, Redlich U, Jain U, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery: A retrospective analysis of safety and efficacy. Crit Care Med. 2005;33:2241-6.
16. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb. 2002;32(Suppl):41-6.
17. Warren O, Mandal K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg. 2007;83:707-14.
18. van de Garde EMW, Bras LJ, Heijmen RH, et al. Low-dose recombinant factor VIIa in the management of uncontrolled postoperative hemorrhage in cardiac surgery patients. J Cardiothorac Vasc Anesth. 2006;20:573-5.
19. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery; a propensity score matched case control analysis. Transfusion. 2005;45:26-34.
20. Bishop C, Renwick WEP, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. Recombinant activated factor VII: Treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg. 2006;81:875-9.